Types segmentation classifies MSSA offerings by product architecture and functional modality. Diagnostic kits are packaged solutions that integrate sample preparation, detection chemistry, and read‑out hardware, catering to both centralized laboratories and decentralized settings. Molecular assays—including real‑time PCR, isothermal amplification, and next‑generation sequencing panels—provide genotype‑level resolution, allowing clinicians to differentiate MSSA from methicillin‑resistant strains and to detect virulence determinants. Culture‑based systems such as selective agar, broth enrichment, and automated incubators remain essential for phenotypic confirmation and antimicrobial susceptibility testing, especially in low‑resource environments. Antibiotic susceptibility testing (AST) platforms combine microdilution, gradient diffusion, and automated growth‑curve analysis to generate minimum inhibitory concentration data, directly informing therapeutic choices. Each type contributes distinct value: kits drive volume sales through repeat purchases, molecular assays command premium pricing due to speed and specificity, culture systems sustain legacy demand, and AST platforms underpin stewardship programs. Together, they constitute the core of the Methicillin‑Susceptible Staphylococcus Aureus segmentation framework, ensuring comprehensive coverage of market needs.
